Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07270887

The Long-term Effect of Remote Ischemic Conditioning on Main Organs in ASVCD Patients With Very High Risks

The Long-term Effect of Remote Ischemic Conditioning on Main Organs in ASVCD Patients With Very High Risks (RICMO-ASCVD): a Prospective, Blinded Endpoint, Multi-center, Cohort Study

Status
Recruiting
Phase
Study type
Observational
Enrollment
2,800 (estimated)
Sponsor
General Hospital of Shenyang Military Region · Academic / Other
Sex
All
Age
40 Years
Healthy volunteers

Summary

Atherosclerotic cardiovascular disease (ASCVD) is a group of disorders sharing atherosclerosis as a common pathological basis, primarily affecting the heart, brain, kidneys, and other peripheral arteries, leading to clinical syndromes characterized mainly by arterial ischemia. It has become the group of diseases with the highest morbidity and mortality rates worldwide. Patients with very high-risk ASCVD face an even greater risk of recurrence. Previous studies have discovered that remote ischemic conditioning (RIC) has protective effects on major organs such as the heart, brain, and kidneys. Given the cardiorenal and cerebrovascular protective effects of RIC, the invesitgators believe that long-term remote ischemic conditioning is a promising approach to preventing the recurrence of ASCVD events. Based on this hypothesis, the investigators have designed a prospective, multicenter cohort study with blinded outcome assessment to investigate the protective effects of long-term remote ischemic conditioning in very high-risk ASCVD populations.

Conditions

Interventions

TypeNameDescription
DEVICEremote ischemic conditioning5 cycles of cuff inflation for 5 minutes and deflation for 5 minutes to the bilateral upper limbs to 200 mmHg

Timeline

Start date
2025-11-19
Primary completion
2027-12-30
Completion
2027-12-30
First posted
2025-12-08
Last updated
2025-12-08

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT07270887. Inclusion in this directory is not an endorsement.